Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018164526) COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS, CONTAINING ATORVASTATIN AS ACTIVE INGREDIENT
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/164526 International Application No.: PCT/KR2018/002810
Publication Date: 13.09.2018 International Filing Date: 09.03.2018
IPC:
A61K 31/40 (2006.01) ,A61K 31/404 (2006.01) ,A61K 31/366 (2006.01) ,A61K 9/28 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
403
condensed with carbocyclic rings, e.g. carbazole
404
Indoles, e.g. pindolol
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
365
Lactones
366
having six-membered rings, e.g. delta-lactones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
20
Pills, lozenges or tablets
28
Dragees; Coated pills or tablets
Applicants:
아주대학교산학협력단 AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION [KR/KR]; 경기도 수원시 영통구 월드컵로 206 206, World cup-ro, Yeongtong-gu Suwon-si Gyeonggi-do 16499, KR
Inventors:
정연훈 CHOUNG, Yun-Hoon; KR
이윤영 LEE, Yun Yeong; KR
추옥성 CHOO, Oak-Sung; KR
Agent:
이처영 LEE, Cheo Young; KR
장제환 CHANG, Je Hwan; KR
Priority Data:
10-2017-003007509.03.2017KR
10-2017-012125809.03.2017KR
Title (EN) COMPOSITION FOR PREVENTING OR TREATING HEARING LOSS, CONTAINING ATORVASTATIN AS ACTIVE INGREDIENT
(FR) COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DE LA PERTE D'AUDITION, CONTENANT DE L'ATORVASTATINE EN TANT QUE PRINCIPE ACTIF
(KO) 아토르바스타틴을 유효성분으로 포함하는 난청의 예방 또는 치료용 조성물
Abstract:
(EN) The present invention relates to a composition for preventing or treating hearing loss, containing an HMG-CoA reductase inhibitor and, more specifically, to a composition for preventing or treating diabetes-mediated hearing loss, containing, as an active ingredient(s), one or more types selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin. A pharmaceutical composition containing an HMG-CoA reductase inhibitor, according to the present invention, inhibits auditory cell death caused by diabetes, and thus is very useful as an agent for preventing or treating diabetes-mediated sensorineural hearing loss.
(FR) La présente invention concerne une composition destinée à prévenir ou à traiter une perte d'audition, contenant un inhibiteur de la HMG-CoA réductase et, plus spécifiquement, une composition destinée à prévenir ou à traiter une perte d'audition induite par le diabète, contenant, en tant que principe(s) actif(s), un ou plusieurs type(s) choisi(s) dans le groupe constitué par l'atorvastatine, la fluvastatine, la lovastatine, la pitavastatine, la pravastatine, la rosuvastatine et la simvastatine. Une composition pharmaceutique contenant un inhibiteur de la HMG-CoA réductase, selon la présente invention, inhibe la mort des cellules auditives provoquée par le diabète, ce qui la rend très utile en tant qu'agent pour prévenir ou traiter la perte d'audition sensorielle induite par le diabète.
(KO) 본 발명은 HMG-CoA 환원효소 저해제를 포함하는 난청 예방 또는 치료용 조성물에 관한 것으로, 더욱 자세하게는 아토르바스타틴, 플루바스타틴, 로바스타틴, 피타바스타틴, 프라바스타틴, 로수바스타틴 및 심바스타틴으로 구성된 군에서 선택된 1종 이상을 유효성분으로 함유하는 당뇨매개성 난청의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 HMG-CoA 환원효소(reductase) 저해제를 포함하는 약학 조성물은 당뇨에 의해 유발된 청각세포의 사멸을 억제하므로, 당뇨매개성 감각신경계 난청의 예방 또는 치료제로 매우 유용하다.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Korean (KO)
Filing Language: Korean (KO)